Unmasking CME Group’s True Worth: A 32% Rally in Sight?
CME Group Valuation Analysis Suggests Overvaluation by 43.9%
The CME Group, a leading financial services company, has seen impressive gains in recent months, with its stock price up 3.1% over the past week and 6.4% in the last month. This builds on a strong year-to-date return of 22.5% and an impressive 32.2% gain over the past year. The company’s continued focus on market innovation and expansion of derivatives offerings has contributed to its position in an ever-evolving financial landscape.
However, despite this momentum, CME Group scores just 1 out of 6 on our valuation checks, indicating that there may be more beneath the surface to unpack. Let’s break down how different valuation methods stack up when it comes to evaluating CME Group’s value.
Approach 1: Excess Returns Analysis
The Excess Returns valuation model takes a unique approach by measuring how much value a company can generate over and above the required return for its equity holders. It focuses on the company’s return on invested capital, compared to what investors demand for providing their funds. For CME Group, this model uses a Book Value of $78.34 per share and projects a Stable Earnings Per Share (EPS) of $12.36. These EPS projections are based on weighted future Return on Equity estimates from seven analysts, with an average Return on Equity of 15.40%. The Cost of Equity, or the shareholder’s required return, stands at $6.56 per share.
By subtracting this cost from projected stable earnings, CME achieves an annual Excess Return of $5.80 per share. Analysts also estimate the company’s Stable Book Value to rise to $80.22 per share in the future. Applying this model yields an intrinsic value for CME Group of $198.10 per share. Since CME’s current stock price is significantly higher than this estimate, the implied discount suggests that the stock is 43.9% overvalued.
Result: OVERVALUED
Our Excess Returns analysis suggests that CME Group may be overvalued by 43.9%. This raises important questions about whether the company’s current valuation accurately reflects its underlying worth.
Approach 2: Price vs Earnings Analysis
The Price-to-Earnings (PE) ratio is one of the most widely used valuation tools for profitable companies like CME Group. It provides investors with a quick snapshot of how much they are paying for each dollar of earnings, making it particularly helpful for comparing companies in the same sector. A "normal" or "fair" PE ratio is influenced by expectations for future growth and the risks involved.
CME Group currently trades at a PE ratio of 27.7x. For context, the Capital Markets industry average PE sits at 24.6x, while the average among CME’s peers is 32.9x. These benchmarks reflect general market sentiment but do not necessarily account for company-specific factors. This is where Simply Wall St’s "Fair Ratio" comes in.
The Fair Ratio
The Fair Ratio takes into account factors such as CME’s projected earnings growth, market capitalization, profit margins, and company-specific risks. By tailoring the multiple to these nuances, the Fair Ratio offers a more accurate sense of what investors should be willing to pay for CME’s earnings power.
Comparing CME’s current PE of 27.7x to its Fair Ratio of 15.2x, the stock appears to be trading at a considerable premium, suggesting that the valuation is stretched well above what would be justified by its fundamentals at this time.
Result: OVERVALUED
Our analysis suggests that CME Group may be overvalued, with the current stock price significantly higher than what is justified by its underlying value.
Narratives Approach to Valuation
Earlier we mentioned that there is an even better way to understand valuation. Let’s introduce you to Narratives, which offers a unique approach to evaluating companies like CME Group. A Narrative is simply the story you tell to explain what you believe about a company, and importantly, it turns those beliefs into financial forecasts and a personal estimate of fair value.
By connecting a company’s real-world story to actual revenue, earnings, and margin forecasts, Narratives help you see exactly how your view translates into what you think the stock is worth. This approach makes analysis more accessible and dynamic, allowing anyone to use Narratives right within the Community page on Simply Wall St.
Conclusion
In conclusion, our valuation checks suggest that CME Group may be overvalued by 43.9%. While the company has seen impressive gains in recent months, its current stock price appears to be trading at a considerable premium. We recommend caution when considering an investment in CME Group and encourage investors to consider alternative views and perspectives on the company’s value.
Moreover, our analysis highlights the importance of using multiple valuation methods to get a comprehensive understanding of a company’s underlying worth. By combining different approaches, such as Excess Returns and Price vs Earnings analysis, we can gain a more nuanced perspective on CME Group’s valuation.
Ultimately, investing in the stock market requires ongoing research and analysis. We encourage investors to stay informed and keep an eye on CME Group’s performance over the coming months.
Unmasking CME Group’s True Worth: A 32% Rally in Sight?
CME Group Valuation Analysis Suggests Overvaluation by 43.9%
The CME Group, a leading financial services company, has seen impressive gains in recent months, with its stock price up 3.1% over the past week and 6.4% in the last month. This builds on a strong year-to-date return of 22.5% and an impressive 32.2% gain over the past year. The company’s continued focus on market innovation and expansion of derivatives offerings has contributed to its position in an ever-evolving financial landscape.
However, despite this momentum, CME Group scores just 1 out of 6 on our valuation checks, indicating that there may be more beneath the surface to unpack. Let’s break down how different valuation methods stack up when it comes to evaluating CME Group’s value.
Approach 1: Excess Returns Analysis
The Excess Returns valuation model takes a unique approach by measuring how much value a company can generate over and above the required return for its equity holders. It focuses on the company’s return on invested capital, compared to what investors demand for providing their funds. For CME Group, this model uses a Book Value of $78.34 per share and projects a Stable Earnings Per Share (EPS) of $12.36. These EPS projections are based on weighted future Return on Equity estimates from seven analysts, with an average Return on Equity of 15.40%. The Cost of Equity, or the shareholder’s required return, stands at $6.56 per share.
By subtracting this cost from projected stable earnings, CME achieves an annual Excess Return of $5.80 per share. Analysts also estimate the company’s Stable Book Value to rise to $80.22 per share in the future. Applying this model yields an intrinsic value for CME Group of $198.10 per share. Since CME’s current stock price is significantly higher than this estimate, the implied discount suggests that the stock is 43.9% overvalued.
Result: OVERVALUED
Our Excess Returns analysis suggests that CME Group may be overvalued by 43.9%. This raises important questions about whether the company’s current valuation accurately reflects its underlying worth.
Approach 2: Price vs Earnings Analysis
The Price-to-Earnings (PE) ratio is one of the most widely used valuation tools for profitable companies like CME Group. It provides investors with a quick snapshot of how much they are paying for each dollar of earnings, making it particularly helpful for comparing companies in the same sector. A "normal" or "fair" PE ratio is influenced by expectations for future growth and the risks involved.
CME Group currently trades at a PE ratio of 27.7x. For context, the Capital Markets industry average PE sits at 24.6x, while the average among CME’s peers is 32.9x. These benchmarks reflect general market sentiment but do not necessarily account for company-specific factors. This is where Simply Wall St’s "Fair Ratio" comes in.
The Fair Ratio
The Fair Ratio takes into account factors such as CME’s projected earnings growth, market capitalization, profit margins, and company-specific risks. By tailoring the multiple to these nuances, the Fair Ratio offers a more accurate sense of what investors should be willing to pay for CME’s earnings power.
Comparing CME’s current PE of 27.7x to its Fair Ratio of 15.2x, the stock appears to be trading at a considerable premium, suggesting that the valuation is stretched well above what would be justified by its fundamentals at this time.
Result: OVERVALUED
Our analysis suggests that CME Group may be overvalued, with the current stock price significantly higher than what is justified by its underlying value.
Narratives Approach to Valuation
Earlier we mentioned that there is an even better way to understand valuation. Let’s introduce you to Narratives, which offers a unique approach to evaluating companies like CME Group. A Narrative is simply the story you tell to explain what you believe about a company, and importantly, it turns those beliefs into financial forecasts and a personal estimate of fair value.
By connecting a company’s real-world story to actual revenue, earnings, and margin forecasts, Narratives help you see exactly how your view translates into what you think the stock is worth. This approach makes analysis more accessible and dynamic, allowing anyone to use Narratives right within the Community page on Simply Wall St.
Conclusion
In conclusion, our valuation checks suggest that CME Group may be overvalued by 43.9%. While the company has seen impressive gains in recent months, its current stock price appears to be trading at a considerable premium. We recommend caution when considering an investment in CME Group and encourage investors to consider alternative views and perspectives on the company’s value.
Moreover, our analysis highlights the importance of using multiple valuation methods to get a comprehensive understanding of a company’s underlying worth. By combining different approaches, such as Excess Returns and Price vs Earnings analysis, we can gain a more nuanced perspective on CME Group’s valuation.
Ultimately, investing in the stock market requires ongoing research and analysis. We encourage investors to stay informed and keep an eye on CME Group’s performance over the coming months.